The topic of this article may not meet Wikipedia's notability guideline for academics. (July 2024) |
Nadav Ahituv is the Director for the Institute for Human Genetics at the University of California, San Francisco (USCF).[1][2][3] He is also a Professor in the Department of Bioengineering and Therapeutic Sciences and leads the Ahituv Lab at University of California, San Francisco (USCF).[1][4]
Early life and education
editAhituv received his PhD with distinction in human genetics from Tel-Aviv University, where he worked on hereditary hearing loss.[1][3][2]
Research
editAhituv developed cis-regulation therapy (CRT) for genetic diseases that are caused due to changes in gene dosage [5][6] and adipose manipulation transplantation (AMT) that engineers fat cells and implants them for therapeutic benefits.[7]
The Ahituv Lab investigates gene regulatory elements and their relationship to human diversity and disease.[4] His lab also focuses on identifying gene regulatory elements and linking nucleotide variation within them to various phenotypes, including morphological differences between species, drug response, and human disease.[8] The lab is one of the developers of massively parallel reporter assays (MPRAs) that allow for high-throughput functional characterization of gene regulatory elements.[9]
Awards and honors
editIn 2014, Ahituv received the ASCPT Leon I. Goldberg young investigator award from The American Society for Clinical Pharmacology and Therapeutics.[10][1] In 2024, Ahituv received the Scientific Achievement Award from the The American Society of Human Genetics (ASHG).[11]
References
edit- ^ a b c d "Nadav Ahituv | UCSF Profiles". profiles.ucsf.edu. Retrieved 2024-03-05.
- ^ a b "Nadav Ahituv". Simons Institute for the Theory of Computing. Retrieved 2024-03-05.
- ^ a b "Speaker Template". PMWC Precision Medicine World Conference. Retrieved 2024-03-05.
- ^ a b "About · Ahituv Lab". Ahituv Lab. Retrieved 2024-03-05.
- ^ Matharu, Navneet (2018-12-13). "CRISPR-mediated activation of a promoter or enhancer rescues obesity caused by haploinsufficiency". Science. 363 (6424): eaau0629. doi:10.1126/science.aau0629. ISSN 1095-9203. PMID 30545847. S2CID 256746336.
- ^ Matharu, Navneet; Ahituv, Nadav (2020-11-01). "Modulating gene regulation to treat genetic disorders". Nature Reviews Drug Discovery. 19 (11): 757–775. doi:10.1038/s41573-020-0083-7. ISSN 1474-1784. PMID 33020616. S2CID 256746336.
- ^ Nguyen, Hai (2023-03-29). "Implantation of engineered adipocytes that outcompete tumors for resources suppresses cancer progression". bioRxiv. doi:10.1101/2023.03.28.534564. PMID 37034710.
- ^ "Nadav Ahituv, PhD". UCSF Institute for Human Genetics. Retrieved 2024-03-05.
- ^ Inoue, Fumitaka; Ahituv, Nadav (2015-09-01). "Decoding enhancers using massively parallel reporter assays". Genomics. 106 (3): 159–164. doi:10.1016/j.ygeno.2015.06.005. PMC 4540663. PMID 26072433.
- ^ "Nadav Ahituv, PhD | Department of Medicine". medicine.ucsf.edu. Retrieved 2024-03-05.
- ^ "2024 ASHG Awards". American Society of Human Genetics. Retrieved 7 October 2024.